11 startups pitch top Houston angel investors at biannual summit

money moves

The Houston Angel Network's investors heard from growing startups in their portfolio — along with a few prospects. Getty Images

The Houston Angel Network checked in with their investors and portfolio companies at their biannual Houston Angel Summit that gathered HAN members, local investors, and startup founders for a day full of educational opportunities, pitches, and fireside chats.

The event, which took place last week at Rice University's Liu Idea Lab for Innovation and Entrepreneurship, featured 11 startups – both new and more familiar to HAN members – pitching their growing companies in hopes of catching the interest of potential investors.

BioMedical Music Solutions

Austin-based BioMedical Music Solutions has a SaaS platform that uses artificial intelligence and music to accelerate rehabilitation at a lower cost. Founder Hope Young explained her years-proven therapy can work its magic in one-third of the time and one-tenth of the cost of traditional physical therapy sessions.

Optelos

Houston-based Optelos has a patented SaaS solution that can transform physical asset images, videos, and documents into what's known as a "Digital Inspection Twin" that can enabling knowledge workers utilizing our unified data management, reality modeling, and in-process artificial intelligence solution, to digitally visualize, analyze and manage their entire asset base.

Pocket Naloxone

Maryland-based Pocket Naloxone is attempting to solve the opioid crisis. The company has a portfolio of over-the-counter drug overdose reversal agents, including a naloxone OTC product.

AI Driller

Houston-based AI Driller is using mathematic algorithms to apply automation on rigs for drilling. The startup can also offer its clients real-time data and cuts out the opportunity for human error.

Cavu Biotherapies

Houston pet immunotherapy company, Cavu Biotherapies, has seen a tremendous amount of growth and is now a treatment partner at 43 clinic providers in 18 states and Canada. Founder Colleen O'Connor says she's seen a near 600 percent growth in revenue over the past year and treated 38 dog cancer patients in that timeframe.

CorInnova

Another Houston company, CorInnova, has created a device from a soft, flexible material that can be easily inserted through a 1-inch incision, and then be used for increase blood pumping in the heart by 50 percent.

Hive Genie

Houston-based Hive Genie is using technology to help beekeepers optimize their pollination operations and monitor hive operations remotely. Gone are the days, Hive Genie hopes, that beekeepers need to suit up to track and maintain their colonies physically.

Siera AI

Austin-based Siera AI is using its AI-enabled cloud IoT platform for logistics solutions and safety improvements in warehouse settings. A goal of the company's, according to its website, is to free humans from these types of dull, dangerous, dirty tasks.

Skycom

The sky's not even the limit for Austin-based Skycom and its airship technology that supplies low-cost cell towers in orbit. The technology can bring down the cost of mobile service providers and allow for growth into new markets.

Tevido

Another Austin company, Tevido uses a pigment cell graft process to use patients' own skin cells to restore normal skin color for patients with vitiligo and pale scars.

Tot Squad

Los Angeles-based Tot Squad emerged as a service-focused company for baby-related tasks and now has emerged as a digital marketplace connecting service providers online to parents and to-be parents for needs like stroller cleaning or carseat installation.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

New UH survey reveals concerns over AI data center growth in Houston

data findings

A new report out of the University of Houston shows that area residents remain wary of the long-term effects of operating data centers.

The recent survey from the University of Houston’s latest SPACE City Panel, conducted by the Center for Public Policy at the Hobby School of Public Affairs, shows that while 85 percent of Houston-area residents use AI, nearly 63 percent oppose the construction of AI data centers within 1 mile of their homes.

Respondents’ concerns centered around data centers’ high energy demand and the area’s power grid reliability. According to the survey, 32 percent of residents who oppose local data center projects would be more likely to support the centers if they relied on renewable energy over fossil fuels.

“Respondents understand that AI can bring economic and educational benefits, but they are also concerned about the physical infrastructure needed to fuel AI, especially data centers,” Soran Mohtadi, post-doctoral fellow at the Hobby School and a researcher on the report, said in a news release. “This physical infrastructure demands more electricity and water, leading to environmental impacts.”

Experts estimate that 6.5 gigawatts of data center capacity will be added to the Texas grid by 2030. And Houston’s data center capacity is predicted to more than double by 2028.

The Electric Reliability Council of Texas also projects electricity demand could reach 218 gigawatts by 2031, which would be more than double the record peak set in August 2023. Data centers are expected to account for 86 gigawatts of that new demand.

Survey respondents also said they are concerned about the state's future water supply, given the large amounts of water that data centers need to stay cool.

In terms of who’s responsible for that issue, 57.6 percent of respondents said they put the onus on Texas lawmakers, while 31.5 percent say tech companies should be responsible.

Additionally, more than 75 percent of respondents believed that data center developers and technology companies—not residents—should bear the cost of infrastructure upgrades to support data centers.

“Every decision legislators make has implications on residents’ everyday lives and local infrastructure now and in the future,” Maria P. Perez Arguelles, lead researcher on the report and research assistant professor at the Hobby School, added in the news release. “This issue is going to become more important in years to come, so this is just the beginning.”

Read the full report here.

Houston-born Cemvita makes breakthrough in sustainable fuel production

clean fuels

Houston-based biotech company Cemvita announced that it recently reached a critical milestone in the development of its FermOil product, which can be used to create Sustainable Aviation Fuel (SAF) and other renewable fuels at industrial scale.

The company shared in a news release that it completed a 75,000-liter industrial fermentation run at Belgium's Bio Base Europe Pilot Plant.

The campaign achieved target technical metrics for the production of FermOil, Cemvita’s renewable natural oil (RNO). FermOil is produced from industrial crude glycerin, an industrial byproduct, as opposed to traditional sugar-based feedstocks used in many bio-oil fermentation processes. It's designed to be a drop-in feedstock for creating SAFs.

Cemvita had previously advanced its FermOil production process through multiple scale-up stages before successfully reaching the 75,000-liter demonstration campaign, according to the company.

“This is not just a fermentation milestone,” Moji Karimi, CEO at Cemvita, said in the release. “It is a blueprint for how existing industrial infrastructure can evolve into circular bioeconomy infrastructure. Every biodiesel plant generating crude glycerin is a potential platform for renewable natural oil production.”

The milestone also supports the deployment of Cemvita’s industrial biomanufacturing platform, FermWorks, which integrates with existing energy and industrial infrastructure to turn waste carbon streams into SAFs and other materials. According to the release, Cemvita plans to move forward with commercial deployment discussions with partners in Brazil, Europe and in the UK. Cemvita already has a partnership with the Brazilian sustainable research institution REMA.

“We are proud to support innovative companies like Cemvita in scaling breakthrough industrial biotechnology solutions,” Hendrik Waegeman, head of business operations at Bio Base Europe Pilot Plant, added in the release. “Successfully operating at the 75,000-liter scale using a feedstock such as crude glycerin highlights both the maturity of the technology and the quality of the scale-up execution achieved by the Cemvita team.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."
View All Listings